This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Conference Highlights
Advanced Prostate Cancer Consensus Conference (APCCC 2022)
Viewing 1-20 of 49 articles
APCCC 2022: Debate: PSA Directed Treatment for BCR
APCCC 2022: Debate: Imaging Directed Treatment for BCR
APCCC 2022: Who Needs Systemic Treatment With Salvage RT?
APCCC 2022: Biochemical Recurrence After Definitive Radiotherapy of the Prostate – What Are the Local Treatment Options?
APCCC 2022: Who Needs Early Salvage RT and Who Needs Adjuvant RT in 2022?
APCCC 2022: Tumor Genomic Profiling: What Is Relevant and How To Avoid Potential Pitfalls?
APCCC 2022: How To Read a Genomic Testing Report
APCCC 2022: Risk-Adapted Treatment Monitoring in mCRPC
APCCC 2022: Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment
APCCC 2022: Does “Oligoprogressive” Prostate Cancer Exist as a Distinct Clinically Meaningful Entity and if Yes, How To Treat It?
APCCC 2022: How To Follow-Up Patients Who Had PSMA PET As Baseline Imaging
APCCC 2022: How To Interpret and Confirm Lesions Positive on PSMA PET but With No Correlation on CT?
APCCC 2022: What Is the Evidence of Systemic Therapies (Alone or in Combination With MDT) in Oligometastatic mHSPC?
APCCC 2022: How Can Treatment Be Individualized By Using Genomic Classifiers?
APCCC 2022: Can Biology Help Inform Treatment Decisions In the Management of mHSPC?
APCCC 2022: When Low-Volume on Conventional Imaging Goes into High-Volume on Next-Generation Imaging in mHSPC - How Frequent Is This Situation?
APCCC 2022: Genomic and Clinical Markers in nmCRPC
APCCC 2022: Treatment of the Primary or Local Relapse in nmCRPC
APCCC 2022: Treatment De-escalation Strategies in mHSPC
APCCC 2022: The Uptake of New Treatment Options for mHSPC in Real Life -- Education, Access, Use, and Diversity
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free